GMAB News and Press, Genmab A/S From 11/16/20

BioMarin is a leader in rare disease therapy discovery with multiple competitive advantages including scale, expertise, patents and relationships. Two major catalysts for 2021 provide investors with favorable risk/reward skew afforded by a low share price that should not be ignored. ...

BMEZ is a fund that is focused on the healthcare space, more specifically, a focus on the health sciences industry. They overlay this healthcare strategy with an option writing strategy to potentially enhance income. The fund has done exceptionally well since its launch right befo...

The following slide deck was published by Genmab A/S in conjunction with their 2020 Q3 earnings call. For further details see: Genmab A/S 2020 Q3 - Results - Earnings Call Presentation

Genmab A/S (GMAB) announces the initiation of a 480-subject Phase 3 clinical trial comparing bispecific antibody (simultaneously binds to CD3 and CD20) epcoritamab to chemo in patients with diffuse large B-cell lymphoma ((DLBCL)). The primary endpoint is overall survival.The company is co-dev...

Image source: The Motley Fool. Genmab A/S (NASDAQ: GMAB) Q3 2020 Earnings Call Nov 4, 2020 , 12:00 p.m. ET Operator Continue reading For further details see: Genmab A/S (GMAB) Q3 2020 Earnings Call Transcript

Genmab A/S (GMAB) Q3 2020 Earnings Conference Call November 4, 2020 12:00 ET Company Participants Jan van de Winkel - President and Chief Executive Officer Anthony Pagano - Chief Financial Officer Judith Klimovsky - Chief Development Officer Anthony Mancini - Chief Operating Officer Conferenc...

Genmab A/S (GMAB): Q3 GAAP EPS of DKK8.04 beats by $DKK1.88.Revenue of DKK1.72B (+65.4% Y/Y) beats by DKK260M.Press Release For further details see: Genmab A/S EPS beats by DKK1.88, beats on revenue

The first participant has been dosed in an additional arm of a Phase 1b clinical trial evaluating ADC Therapeutics' (ADCT) antibody-drug conjugate camidanlumab tesirine (Cami) (formerly ADCT-301), combined with Merck's (MRK) Keytruda (pembrolizumab), in patients with advanced solid ...

Genmab A/S (GMAB) and ADC Therapeutics SA (ADCT) have amended their 2013 collaboration agreement related to continued development and commercialization of antibody-drug conjugate ((ADC)) camidanlumab tesirine (Cami).The revised contract eliminates the defined divestment process and allows ADC...

Aging population, lifestyle changes and pandemics have created a huge demand for patient-focused healthcare. Biotech stocks like Seagen (SGEN), Genmab A/S (GMAB), Amedisys (AMED), and Masimo (MASI) could dominate the industry based on their disruptive technology, unique offerings and tremendo...